Navigation Links
Forest Laboratories, Inc. and Cypress Bioscience, Inc. Announce Positive Results of Phase III Study of Milnacipran for the Management of Fibromyalgia
Date:12/8/2008

NEW YORK and SAN DIEGO, Dec. 8, 2008 /PRNewswire-FirstCall/ -- Forest Laboratories, Inc. (NYSE: FRX) and Cypress Bioscience, Inc. (Nasdaq: CYPB) today announced positive top-line results from a 1,025 patient, multicenter, double-blind, placebo-controlled phase III study of milnacipran for the management of fibromyalgia. These results, which confirm the findings from the two previous phase III trials, showed that milnacipran demonstrated a highly statistically significant difference to placebo in responder analyses based on a concurrent and clinically meaningful improvement in pain, patient global impression of change, and physical functioning. Comprehensive analyses of the study data will be completed in the coming weeks, and it is anticipated that further results will be presented during 2009.

(Logo: http://www.newscom.com/cgi-bin/prnh/20001011/FORESTLOGO )

Study Background

In this study, designated MLN-MD-03, patients with an established history of fibromyalgia were enrolled at 75 centers in North America and randomized to receive a daily dose of 100 mg of milnacipran (n=516) or placebo (n=509). The design of the double-blind study included a 4 to 6-week dose escalation phase, a 12-week stable-dose treatment phase, and a 2-week discontinuation phase. The primary efficacy endpoints were the proportion of subjects meeting criteria as composite responders based on one of two definitions. In the first co-primary analysis, a patient had to demonstrate simultaneous improvements on both their daily pain ratings (visual analog scale) and on an overall measure of how their fibromyalgia condition had been since the start of the stu
'/>"/>

SOURCE Forest Laboratories, Inc.; Cypress Bioscience, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Daiichi Sankyo and Forest Laboratories Finalize Contract for Co-Promotion of AZOR(TM)
2. Forest Laboratories, Inc. and Gedeon Richter Announce Results of Phase II-B Study for RGH-188 as a Treatment for Schizophrenia
3. Forest Laboratories, Inc. Announces Positive Results of LEXAPRO(R) Phase III Study in Adolescents With Major Depression
4. Microbia and Forest Laboratories Announce Preliminary Results of Linaclotide Phase 2b Studies
5. Forest and Almirall Announce Positive Results of Clinical Studies for Aclidinium Bromide, a Novel, Long-Acting Anticholinergic for the Treatment for COPD
6. Ironwood Pharmaceuticals and Forest Laboratories Announce Presentation of Linaclotide Phase 2b Chronic Constipation Study Results
7. Forest Laboratories Announces Positive Results from Phase III Clinical Studies of Ceftaroline for the Treatment of Complicated Skin and Skin Structure Infections
8. Ironwood and Forest to Present Positive Data From Linaclotide Phase 2b IBS-C Study at ACG Annual Scientific Conference
9. Forest Laboratories, Inc. and Gedeon Richter Plc Announce Positive Phase II Results with the Investigational Antipsychotic Cariprazine in Patients with Acute Mania Associated with Bipolar I Disorder
10. Ironwood and Forest Present Positive Phase 2b Study Results for Linaclotide in Patients With Irritable Bowel Syndrome With Constipation
11. Roxane Laboratories, Inc. Updated Launch of Calcium Acetate Capsules, 667mg
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/3/2015)... , Sept. 3,  2015 About ... bio-artificial devices, which are implanted or integrated ... organs. These include artificial heart, kidney, pancreas, ... polymers (polyurethane, polysulfone, and porous polypropylene), biologics, ... artificial organs. These organs are incorporated with ...
(Date:9/3/2015)... 3, 2015 About dry eye syndrome Dry ... to deficient tear production or quick tear evaporation or ... types: aqueous tear deficient dry eye and evaporative dry ... do not produce enough tears, whereas meibomian gland dysfunction ... to slow tear evaporation and maintain tear stability. The ...
(Date:9/3/2015)... Sept. 3, 2015  Ascendis Pharma A/S ... biotechnology company that applies its innovative TransCon ... today announced plans to present at several ... Healthcare Conference in BostonDate: , Thursday, September ... of America Merrill Lynch Global Healthcare Conference ...
Breaking Medicine Technology:Global Artificial Organ Market 2015-2019 2Global Dry Eye Syndrome Market 2015-2019 2Ascendis Pharma A/S to Present at Three Upcoming Investor Conferences 2
... WIRE)--May 21, 2007 - Cougar Biotechnology,Inc. (OTCBB:CGRB) today ... on the Company's prostate cancer drug candidate CB7630,(abiraterone ... Annual Meeting, which is currently taking place,in Anaheim, ... A.,Yap from the Cancer Research UK Centre for ...
... 40/12.5 and 40/25 mg/day and Amlodipine +,Benazepril ... Society of,Hypertension Twenty-Second Annual Scientific Meeting, PARSIPPANY, ... data,presented today at the American Society of ... Chicago,demonstrated that the fixed-dose combination Benicar HCT,(olmesartan ...
Cached Medicine Technology:Cougar Biotechnology Announces Presentation of Positive CB7630,Clinical Data at AUA Annual Meeting 2Cougar Biotechnology Announces Presentation of Positive CB7630,Clinical Data at AUA Annual Meeting 3Cougar Biotechnology Announces Presentation of Positive CB7630,Clinical Data at AUA Annual Meeting 4Benicar HCT Reductions in Seated Systolic Blood Pressure for Stage,2 Patients Compared With Amlodipine + Benazepril 2Benicar HCT Reductions in Seated Systolic Blood Pressure for Stage,2 Patients Compared With Amlodipine + Benazepril 3Benicar HCT Reductions in Seated Systolic Blood Pressure for Stage,2 Patients Compared With Amlodipine + Benazepril 4Benicar HCT Reductions in Seated Systolic Blood Pressure for Stage,2 Patients Compared With Amlodipine + Benazepril 5Benicar HCT Reductions in Seated Systolic Blood Pressure for Stage,2 Patients Compared With Amlodipine + Benazepril 6Benicar HCT Reductions in Seated Systolic Blood Pressure for Stage,2 Patients Compared With Amlodipine + Benazepril 7Benicar HCT Reductions in Seated Systolic Blood Pressure for Stage,2 Patients Compared With Amlodipine + Benazepril 8
(Date:9/4/2015)... ... 2015 , ... Inmar announced today that its regulatory experts ... Quality and Manufacturers, Dietary Supplements and Supply Chain Committees. , With the complex ... industry, it can be difficult for companies to navigate, stay abreast of all ...
(Date:9/4/2015)... ... September 04, 2015 , ... ... technology is now available at CitiDent. CEREC is a newer method for creating ... saving time for patients by eliminating the need for multiple appointments, CEREC produces ...
(Date:9/4/2015)... ... 04, 2015 , ... Bio-Logic Aqua® Research, a fresh water ... only mission and research focus: Water Life Science®. In the current warming and ... is becoming dangerously accelerated. As a result of the global fresh water, water ...
(Date:9/4/2015)... ... September 04, 2015 , ... ... of its first neighborhood created specifically for adults with intellectual, developmental and acquired ... Metro area and feature 30 cottage or “pocket” homes. In this community, adults ...
(Date:9/4/2015)... ... 04, 2015 , ... Yisrayl Hawkins, Pastor and Overseer at The House of Yahweh, has written ... the Pope’s upcoming trip to the United States. , Yisrayl lays out what he says ... Vatican and society is. Yisrayl also provides the meaning of his own name and describes ...
Breaking Medicine News(10 mins):Health News:Inmar Experts To Address OTC Manufacturers’ Session on Hazardous Waste and Handling at CHPA Meeting 2Health News:Inmar Experts To Address OTC Manufacturers’ Session on Hazardous Waste and Handling at CHPA Meeting 3Health News:San Francisco Dentist, Dr. Ben Amini, is Now Offering CEREC Technology at CitiDent 2Health News:Bio-Logic Aqua® Research Announces Water Life Science and Body Water Evaporation as Research Focus and Mission 2Health News:Bio-Logic Aqua® Research Announces Water Life Science and Body Water Evaporation as Research Focus and Mission 3Health News:Cottage Home Communities for Disabled Adults to Create First Viable Permanent Housing Option 2Health News:Cottage Home Communities for Disabled Adults to Create First Viable Permanent Housing Option 3Health News:Cottage Home Communities for Disabled Adults to Create First Viable Permanent Housing Option 4Health News:Yisrayl Hawkins Writes Open Letter to Pope Francis In Light of Approaching U.S. Visit 2
... other form of treatment. But to a benefit of all GPs ... ,A resident artist much like resident doctors has been ... Susan Grant, a graduate of the Edinburgh School of Art. ... Council. ,It is one of 27 projects across Scotland ...
... Abdul Kalam today met representatives of the striking medicos ... the students and doctors deciding// to continue with their ... also included members of AIIMS Faculty Association who have ... with Kalam. The medicos presented a charter of demands ...
... India's northeast has led to a rise in drug abuse ... United Nations study. ,"Drug trafficking across the common border ... Nagaland occurs with ease. Despite the existence of heavy security, ... the local youths of these states," said a report released ...
... couple has revealed how a mistake at an IVF clinic almost ... spoke of the emotional trauma// that they had to undergo when ... with an Asian man's sperm. ,The couple had twins ... treated at a fertility clinic run by Leeds NHS Trust. "I ...
... can be attributed to genes, says a new finding ... ,Researchers led by Richard P. Ebstein, a professor of ... DNA of 148 healthy male and female Israeli university ... compared the results, they found that common variations in ...
... centres in Singapore and India plan to expand joint ... cancer centre said Tuesday//. ,The cooperation between Singapore's ... Centre builds on a screening programme credited with cutting ... the Indian state by 40 percent. ,The ...
Cached Medicine News:Health News:President Kalam Meets Striking Medicos However Stir to Continue 2Health News:Illegal Drug Trafficking Pose A Great Threat For HIV Epidemic In Northeast 2
Enzyme Immunoassay for the Quantitative Measurement of Ovarian Cancer Antigen CA-125 in Human Serum...
Test for prostatic acid phosphatase...
The MOSAIC PET scanner is designed to meet the exacting requirements of animal research imaging. Supported by proven Philips technology, MOSAIC provides a leading edge PET solution for reliable in-vi...
... iMRI is a neurosurgical OR that ... diagnostic tools, including iMRI, necessary to ... iMRI, neurosurgical treatments are performed in ... designed for MR compatibility and safety, ...
Medicine Products: